A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4Rα Antagonist, in Patients with Asthma

2010293 citationsJournal Article

Authors

Jonathan Corren · Cancer Research Foundation

William W. Busse · University of Wisconsin–Madison

Eli O. Meltzer · Allergy and Asthma Medical Group and Research Center

Lyndon E. Mansfield · Western Sky Medical Research

George Bensch

John M. Fahrenholz · Vanderbilt University Medical Center

Sally E. Wenzel · University of Pittsburgh Medical Center

Abstract

AMG 317 did not demonstrate clinical efficacy across the overall group of patients. Clinically significant improvements were observed in several outcome measures in patients with higher baseline ACQ scores. AMG 317 was safe and well tolerated in this study population. Clinical trial registered with www.clinicaltrials.gov (NCT 00436670).

Topics & Keywords

Asthma and respiratory diseases Respiratory and Cough-Related Research IL-33, ST2, and ILC Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: American Journal of Respiratory and Critical Care Medicine

Volume 181, Issue 8, pp. 788-796

DOI: 10.1164/rccm.200909-1448oc

Field-Weighted Citation Impact: 21.87